Blood cancers lead in CAR-T therapy development: report

Currently, 13 CAR-T treatments have received regulatory approval.

Blood cancers have dominated the development pipeline of chimeric antigen receptor T-cell (CAR-T) therapeutics, according to GlobalData.

“Blood cancers account for over half of all CAR-Ts in the active pipeline and make up nine out of the top 10 CAR-T indications,” the report said.

CAR-T therapies are developed by engineering T-cells to express chimeric antigen receptors capable of identifying and destroying cancerous cells.

The therapy accounts for over half of oncology cell and gene therapy approvals, with 13 CAR-T treatments currently receiving regulatory approval.